The contract service provider entered into a contract agreement with the US Army to provide services in the development of treatments of malaria.
On Dec. 20, 2016, Dalton Pharma Services, a Health Canada-approved and FDA-registered current good manufacturing practice (cGMP) contract service provider of integrated chemistry, drug development, and manufacturing services, announced that it has entered into an agreement with the US Army Medical Material Development Activity (USAMMDA). Dalton will offer services, which include cGMP sterile powder filling, aseptic liquid filling, quality control release testing, and International Council for Harmonization (ICH) stability services, to the USAMMDA’s anti-malarial drug development program. USAMMDA, as part of the US Department of Defense, develops new drugs, vaccines, and medical support equipment to protect and treat military personnel.
“The leadership role taken by USAMMDA in the development of this important therapy for malaria treatment is to be commended, and we are privileged to support this critical program developing safe and effective anti-malarial drugs for emergency treatment protocols,” said Peter Pekos, president and CEO of Dalton, in a press release.
Source: Dalton Pharma Services
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.